Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 430-434, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, H.
Right arrow Articles by Stamey, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, H.
Right arrow Articles by Stamey, T. A.

Clinical Chemistry, Vol 41, 430-434, Copyright © 1995 by American Association for Clinical Chemistry

Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy

H Yu, EP Diamandis, AF Prestigiacomo and TA Stamey
Department of Clinical Biochemistry, Toronto Hospital, Ontario.

We used an ultrasensitive prostate-specific antigen (PSA) assay with a detection limit of 0.02 microgram/L for long-term monitoring of PSA changes in 5 patients who were cured by radical prostatectomy and in 10 patients who had failed prostatectomies; 5 patients who underwent cystoprostatectomy were also evaluated with one sample after surgery. Relapse-free periods, determined on the basis of criteria designed specifically for the ultrasensitive assay or proposed for other currently available PSA assays, were calculated for the patients with failed prostatectomies. Tumor-doubling times were also calculated, postsurgery, according to a model that assumes exponential tumor growth over time. We found that prostate cancer relapse, on average, could be diagnosed 420 or 883 days earlier with the ultrasensitive assay than with assays having detection limits of 0.1 or 0.3 microgram/L, respectively. Tumor-doubling times, calculated after radical prostatectomy, ranged from 67 to 568 days among the 10 patients. We also present evidence that even more-sensitive PSA assays might be able to further reduce the relapse-free periods in approximately 50% of the prostate cancer patients who ultimately relapse.


The following articles in journals at HighWire Press have cited this article:


Home page
 Jpn J Clin OncolHome page
F. Shimizu, S. Tanaka, Y. Matsuyama, T. Tominaga, Y. Ohashi, and M. Fujime
Efficiency of Ultrasensitive Prostate-specific Antigen Assay in Diagnosing Biochemical Failure After Radical Prostatectomy
Jpn. J. Clin. Oncol., June 1, 2007; 37(6): 446 - 451.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
J.-M. Nam, C. S. Thaxton, and C. A. Mirkin
Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins
Science, September 26, 2003; 301(5641): 1884 - 1886.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Eriksson, M. Vehniainen, T. Jansen, V. Meretoja, P. Saviranta, K. Pettersson, and T. Lovgren
Dual-Label Time-resolved Immunofluorometric Assay of Free and Total Prostate-specific Antigen Based on Recombinant Fab Fragments
Clin. Chem., May 1, 2000; 46(5): 658 - 666.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S.-F. Chen, Y. Xu, and M. P.-C. Ip
Electrochemical Enzyme Immunoassay for Serum Prostate-Specific Antigen at Low Concentrations
Clin. Chem., August 1, 1997; 43(8): 1459 - 1461.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.